GSK Pharma Board Approves Sale Of Vemgal Plant To Hetero Labs: ICICI Securities Analysis
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
GlaxoSmithKline Pharmaceuticals Ltd. has announced the sale of its Vemgal plant located in Karnataka to Hetero Labs Ltd. for a cash consideration of Rs 1.8 billion.
Post discontinuation of Zinetac last year this plant remained unutilized and the company had announced a writeoff on it.
Company’s recent financial performance was healthy led by recovery in its key brands and supported by recently launched products (Fluarix Tetra, Menveo and Nucala).
We expect this trend in recovery in the acute therapies to continue in the coming quarters.
GSK Pharma’s exposure only to domestic formulations, strong balance sheet and strong brand equity augurs well.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.